Notably, the observed dissociation between PD-L1 expression levels and clinical outcomes challenges the biomarker paradigm established in NSCLC, underscoring the biological uniqueness of SCLC immune regulation. The gene discussed is CD274; the disease is small cell lung carcinoma.